1	HOUSE OF REPRESENTATIVES - FLOOR VERSION
2	STATE OF OKLAHOMA
3	2nd Session of the 56th Legislature (2018)
4	HOUSE CONCURRENT
5	RESOLUTION 1017 By: Fetgatter
6	
7	
8	AS INTRODUCED
9	A Concurrent Resolution recognizing October 2018 as
10	Eczema Awareness Month; and encouraging the show of support for eczema awareness.
11	Support for cozema awareness.
12	
13	WHEREAS, eczema is a set of skin conditions that cause red,
14	itchy, and inflamed skin, and has profound medical, psychosocial,
15	and economic impacts on patients, families, and their communities;
16	and
17	WHEREAS, the prevalence of eczema in the United States is 10.1
18	percent; and
19	WHEREAS, eczema impacts over 31.6 million children and adults in
20	the United States alone; and
21	WHEREAS, eczema's medical impacts include dry, cracked, and
22	scaly skin; incessant itch, chronic pain, and sleep deprivation; and
23	
24	

WHEREAS 41.5 percent of adult eczema patients report having a concurring diagnosis of depression and 47.9 percent report having a concurring diagnosis of asthma; and

WHEREAS, adults and children with eczema frequently also experience comorbidities like asthma, allergic rhinitis, food allergies, attention-deficit/hyperactivity disorder (ADHD), bacterial and viral infections, and hypertension; and

WHEREAS, eczema's disease burden also includes anxiety, stress on social and intimate relationships, increased suicidal ideation, delayed developmental achievement, reduced self-esteem, restrictions on diet and exercise, extensive caregiver burdens, and challenges with medication adherence; and

WHEREAS, eczema results in missed days of school and work for patients and caregivers, disability and reduced ability within a patient's chosen profession, unemployment and underemployment, and other opportunity costs; and

WHEREAS, the direct medical costs of the three most common types of eczema exceed \$2.17 Billion and the indirect medical costs exceed \$927 Million; and

WHEREAS, two-thirds of eczema patients report experiencing significant access barriers, including high out-of-pocket costs and insurance requirements that delay patients' access to medications; and

1.3

1	WHEREAS, there is no cure for eczema but emerging technologies
2	and medications promise a much brighter future for eczema patients
3	NOW, THEREFORE, BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES
4	OF THE 2ND SESSION OF THE 56TH OKLAHOMA LEGISLATURE, THE SENATE
5	CONCURRING THEREIN:
6	THAT the month of October 2018 is hereby declared to be Eczema
7	Awareness Month in Oklahoma.
8	THAT the Oklahoma House of Representatives wishes to show its
9	support and encourages all constituents to show support for eczema
10	awareness.
11	
12	DIRECT TO CALENDAR.
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	